NMN Evidence Center

Nicotinamide Mononucleotide (NMN) Research

Every peer-reviewed paper HealthspanX references on NMN has a dedicated analysis page on this site. Each entry is populated directly from the source publication and verified against PubMed. This hub aggregates the current NMN corpus, grouped by the biological system studied.

Human-trial findings are presented as findings in people. Preclinical mouse and in-vitro findings are labelled as such and are not used to predict outcomes in people.

Browse study records Review the method

Evidence types

Human findings, reviews, and mechanisms are not interchangeable.

A study finding is limited to the product or formulation, population, dose, duration, comparison, and endpoints examined. It is not a prediction of an individual RL100 record.

Human studies

8 intervention records in people, with positive, mixed, and null findings shown together.

Reviews and perspectives

6 interpretive records. These synthesize other publications and contain no original controlled human outcomes.

Preclinical and mechanistic

4 animal, cellular, structural, or other non-human records used for mechanistic context, not consumer outcomes.

Claim boundary: HealthspanX does not use these records to state that NMN supports all 12 wellbeing areas. RL100 documents 12 self-reported areas while the participant follows a standardized NMN protocol.

Study library

18 public records, grouped by evidence type.

Human studies

Original intervention research conducted in people.

  • Evidence type: Human randomized trial Interpretive weight: Moderate

    Mihoko Yoshino et al., 2021 —Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

    Science · Metabolic measures

    Full analysis
  • Evidence type: Human randomized trial Interpretive weight: Moderate

    Liao B et al., 2021 —Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study

    Journal of the International Society of Sports Nutrition · Exercise physiology

    Full analysis
  • Evidence type: Early human intervention Interpretive weight: Limited

    Junichiro Irie et al., 2020 —Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

    Endocrine Journal · Short-term tolerability and metabolism

    Full analysis
  • Evidence type: Human randomized trial Interpretive weight: Moderate

    Karol M. Pencina et al., 2023 —MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

    The Journals of Gerontology: Series A, Biological Sciences and Medical Sciences · Pharmacokinetics and short-term safety

    Full analysis
  • Evidence type: Human randomized trial Interpretive weight: Moderate

    Mijin Kim et al., 2022 —Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study

    Nutrients · Sleep-related and physical-function measures

    Full analysis
  • Evidence type: Human randomized trial Interpretive weight: Limited

    Takeshi Katayoshi et al., 2023 —Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial

    Scientific Reports · Vascular and NAD-related measures

    Full analysis
  • Evidence type: Early human intervention Interpretive weight: Limited

    Shintarou Kimura et al., 2022 —Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals

    Cureus · Intravenous NMN metabolism and short-term tolerability

    Full analysis
  • Evidence type: Human randomized trial Interpretive weight: Moderate

    Stefan Christen et al., 2026 —The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans

    Nature Metabolism · NAD+ precursor metabolism and microbiome

    Full analysis

Reviews and perspectives

Interpretive publications that synthesize or discuss other evidence.

  • Evidence type: Narrative perspective Interpretive weight: Limited

    Christopher Shade, 2020 —The Science Behind NMN—A Stable, Reliable NAD+ Activator and Anti-Aging Molecule

    Integrative Medicine (Encinitas) · NAD+ metabolism and delivery claims

    Full analysis
  • Evidence type: Narrative review Interpretive weight: Limited

    Deokho Lee et al., 2024 —Nicotinamide mononucleotide, a potential future treatment in ocular diseases

    Graefe's Archive for Clinical and Experimental Ophthalmology · Ocular research

    Full analysis
  • Evidence type: Narrative review Interpretive weight: Limited

    Harshani Nadeeshani et al., 2022 —Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns

    Journal of Advanced Research · Anti-aging claims and safety

    Full analysis
  • Evidence type: Narrative review Interpretive weight: Limited

    Candace Benjamin et al., 2024 —Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications

    Metabolites · Metabolic variability and bioavailability

    Full analysis
  • Evidence type: Narrative review Interpretive weight: Limited

    Qin Song et al., 2023 —The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

    Advances in Nutrition · Human safety and anti-aging evidence

    Full analysis
  • Evidence type: Narrative review Interpretive weight: Limited

    Bin Yu et al., 2024 —The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications

    Frontiers in Pharmacology · NMN pharmacology, clinical evidence and applications

    Full analysis

Preclinical and mechanistic research

Animal, cellular, structural, or other non-human evidence.

  • Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic context

    M Di Stefano et al., 2015 —A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration

    Cell Death & Differentiation · Axon-injury biology

    Full analysis
  • Evidence type: Cellular and structural study Interpretive weight: Mechanistic context

    Yun Nan Hou et al., 2022 —A conformation-specific nanobody targeting the nicotinamide mononucleotide-activated state of SARM1

    Nature Communications · SARM1 activation

    Full analysis
  • Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic context

    Takuya Kawamura et al., 2023 —Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice

    ASN Neuro · Neonatal hypoxic–ischemic brain injury

    Full analysis
  • Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic context

    Kazuhiro Hasegawa et al., 2022 —Nicotinamide mononucleotide ameliorates adriamycin-induced renal damage by epigenetically suppressing the NMN/NAD consumers mediated by Twist2

    Scientific Reports · Renal injury and NAD+ metabolism

    Full analysis

Review method

Every record answers the same questions.

1. Verify the source

Check citation, DOI, PMID, publication type, design, population, intervention, endpoints, funding, and conflicts.

2. Separate the evidence

Keep human outcomes distinct from reviews, animal findings, cellular mechanisms, and product credentials.

3. State the boundary

Show null findings and limitations beside positive findings. Do not translate a narrow endpoint into a broad support claim.

Within RL100

Research describes study groups. RL100 documents the participant's own window.

Ultra Pure™ NMN is the current Foundation Product within the Foundation Protocol. RL100 records Day 0, Day 30, and Day 100 across 12 self-reported areas without promising a particular outcome.

Explore RL100 Review Ultra Pure NMN